Zacks.com on MSN15h
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage ListEli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...
Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...
The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...
US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback